Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Go back to Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer| (NASDAQ: CRBP) | Delayed: 8.12 -0.12 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.24 | 52 Week High | $10.78 | |||
| Open | $8.38 | 52 Week Low | $1.01 | |||
| Day High | $8.50 | P/E | N/A | |||
| Day Low | $7.95 | EPS | $0.00 | |||
| Volume | 2,268,595 | |||||
